Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement

Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma

(2012) Bridget Charbonneau et al.   AMERICAN JOURNAL OF HEMATOLOGY

Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies

(2012) Marcin Okroj et al.   CANCER TREATMENT REVIEWS

Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy

(2012) L. Bologna et al.   JOURNAL OF IMMUNOLOGY

Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients

(2012) F. J. Beurskens et al.   JOURNAL OF IMMUNOLOGY

Functional Analyses of Complement Convertases Using C3 and C5-Depleted Sera

(2012) Marcin Okroj et al.   PLoS One

Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma

(2011) Matthew J. Barth et al.   BRITISH JOURNAL OF HAEMATOLOGY

rILYd4, a Human CD59 Inhibitor, Enhances Complement-Dependent Cytotoxicity of Ofatumumab against Rituximab-Resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia

(2011) X. Ge et al.   CLINICAL CANCER RESEARCH

Ofatumumab: A New CD20 Monoclonal Antibody Therapy for B-Cell Chronic Lymphocytic Leukemia

(2010) Susan O'Brien et al.   Clinical Lymphoma Myeloma & Leukemia

Molecular mechanisms of the antitumor effects of anti-CD20 antibodies

(2010) Magdalena Winiarska   Frontiers in Bioscience-Landmark

Complement: coming full circle

(2009) Gaëlle Le Friec et al.   ARCHIVUM IMMUNOLOGIAE ET THERAPIAE EXPERIMENTALIS